These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8428324)

  • 21. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
    Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.
    Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D
    World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
    Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
    Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
    Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    Moschini M; Sharma V; Gandaglia G; Dell'Oglio P; Fossati N; Zaffuto E; Montorsi F; Briganti A; Karnes RJ
    BJU Int; 2017 Jul; 120(1):69-75. PubMed ID: 27753192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended pelvic lymph-node dissection and radiotherapy with curative intent in high-risk lymph-node-positive prostate cancer: a possible curative strategy?
    Al-Amiri B; Lundin F; Waldén M
    Scand J Urol; 2018 Apr; 52(2):101-107. PubMed ID: 29020868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.
    Gandaglia G; Briganti A; Clarke N; Karnes RJ; Graefen M; Ost P; Zietman AL; Roach M
    Eur Urol; 2017 Nov; 72(5):689-709. PubMed ID: 28189428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
    Häcker A; Jeschke S; Leeb K; Prammer K; Ziegerhofer J; Sega W; Langsteger W; Janetschek G
    J Urol; 2006 Nov; 176(5):2014-8; discussion 2018-9. PubMed ID: 17070241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal treatment of locally advanced prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    World J Urol; 2007 Apr; 25(2):169-76. PubMed ID: 17333200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy.
    Cheng CW; Bergstralh EJ; Zincke H
    Cancer; 1993 Feb; 71(3 Suppl):996-1004. PubMed ID: 7679047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
    Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
    World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pelvic lymph node dissection in prostate cancer.
    Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
    Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.